It’s only fair to share… Admilparant, (BMS-986278) CAS 2170126-74-4 MF C22H31N5O5 MW 445.5 g/mol (1S,3S)-3-({2-methyl-6-[1-methyl-5-({[methyl(propyl)carbamoyl]oxy}methyl)-1H-1,2,3-triazol-4-l]pyridin-3-yl}oxy)cyclohexane-1-carboxylic acidlysophosphatidic acid receptor 1 (LPA1) antagonist Admilparant is an investigational new drug being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist.[1][2] As of 2024, admilparant is in Phase III clinical trials …
Tag «PHASE 3»
Sergliflozin Etabonate
It’s only fair to share… Sergliflozin Etabonate 408504-26-7 Cas no Ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate 2-(4-methoxybenzyl)phenyl 6-O-ethoxycarbonyl-beta-D-glucopyranosideethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]tetrahydropyran-2-yl]methyl carbonateethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-{2-[(4-methoxyphenyl)methyl]phenoxy}oxan-2-yl]methyl carbonate PHASE 2……….TYPE 3 DIABETES AND OBESITYA SGLT-2 inhibitor potentially for the treatment of type 2 diabetes and obesity. GW-869682; GW-869682X; KGT-1251 MW 448.4, C23H28O9 KISSEI INNOVATORGSK DEVELOPER Sergliflozin Etabonate is a benzylphenol glucoside and selective sodium-glucose co-transporter …
Baxdrostat
It’s only fair to share… Baxdrostat WeightAverage: 363.461Monoisotopic: 363.194677057 Chemical FormulaC22H25N3O2 N-[(8R)-4-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide Baxdrostat is an investigational drug that is being evaluated for the treatment of hypertension.[1] It is an aldosterone synthase inhibitor.[2][3] Baxdrostat is under investigation in clinical trial NCT06344104 (A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Asian Participants With Uncontrolled Hypertension on Two or More …
DAZDOTUFTIDE
It’s only fair to share… DAZDOTUFTIDE C43H68N13O13P 1006.1 g/mol L-Tyrosine, L-threonyl-L-lysyl-L-prolyl-L-arginylglycyl-3-[(1E)-2-[4-[[hydroxy[2-(trimethylammonio)ethoxy]phosphinyl]oxy]phenyl]diazenyl]-, inner salt L-threonyl-L-lysyl-L-prolyl-L-arginylglycyl-3-{(E)-[4- ({oxido[2-(trimethylazaniumyl)ethoxy] phosphoryl}oxy)phenyl]diazenyl}-L-tyrosine SQ 1 TKPRGY Protein/Peptide Sequence, Sequence Length: 6 modified (modifications unspecified) Molecular Formula C43H68N13O13P.C2HF3O2 Molecular Weight 1120.0764 TRS01 trifluoroacetateTRS-01 trifluoroacetateI35XEI0JIK CAS 2522933-45-34-((E)-(5-(2-(2-((S)-2-((S)-1-(L-Threonyl-L-lysyl)pyrrolidine-2-carboxamido)-5-guanidinopentanamido)acetamido)-2-carboxyethyl)-2-hydroxyphenyl)diazenyl)phenyl (2-(trimethylammonio)ethyl) phosphate, trifluoroacetate salt Ocular inflammation, an inflammation of any part of the eye, is one of the most common …
CEFILAVANCIN
It’s only fair to share… CEFILAVANCIN, TD-1792 CAS 722454-12-8 C87H96Cl3N16O28S2, 1984.28 F76229E21M Vancomycin, 26-[[[3-[[(Z)-[1-(2-amino-5-chloro-4-thiazolyl)-2-[[(6R,7R)-2-carboxy-8-oxo-3-(pyridiniomethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxoethylidene]amino]oxy]propyl]amino]carbonyl]-26-decarboxy- 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-[(3-{[(1S,2R,18R,19R,22S,25R,28R,40S)-48-{[(2S,3R,4S,5S,6R)-3-{[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-22-(carbamoylmethyl)-5,47-dichloro-2,18,32,35,37-pentahydroxy-19-[(2R)-4-methyl-2-(methylamino)pentanamido]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2^{3,6}.2^{14,17}.1^{8,12}.1^{29,33}.0^{10,25}.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaen-40-yl]formamido}propoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium Phase III Skin and soft tissue infections BUILDING BLOCK Vancomycin, Formula C66H75Cl2N9O24 Molar mass 1449.27 g·mol−1 Cefilavancin (TD-1792) is an experimental antibiotic medication developed for the treatment of bacterial infections such as drug-resistant strains of Staphylococcus aureus. It is a prodrug which is also a codrug, injected intravenously …
BOFUTRELVIR
It’s only fair to share… BOFUTRELVIR Cas 2103278-86-8 Molecular Weight 452.55 Formula C25H32N4O4 UNII-T5UX5SKK2S; Mpro inhibitor 11A; 2103278-86-8; T5UX5SKK2S, DC-402234, DC402234, MPI-10 IUPAC/Chemical Name: N-[(2S)-3-cyclohexyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1H-indole-2-carboxamide N-[(2S)-3-cyclohexyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1H-indole-2-carboxamide Bofutrelvir has an additive antiviral effect when combined with Remdesivir FB2001 Bofutrelvir (FB2001) is a SARS-CoV-2 main protease Mpro inhibitor with an IC50 value of 53 nM and an EC50 value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy …
Tibremciclib
It’s only fair to share… Tibremciclib cas 2397678-18-9, GTPL12881 CRB7BT5JDQ 518.6 g/mol, C28H32F2N8 N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-[(1R)-6-fluoro-1-methyl-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-8-yl]pyrimidin-2-amine Tibremciclib is a CDK4 inhibitor with antineoplastic activity[1]. 13 Sep 2024 Efficacy and adverse event data from a phase III trial in Breast cancer presented at the 49th European Society for Medical Oncology Congress 2024 (ESMO-2024) Cyclin-dependent kinases (CDKs) are a class of serine …
ATICAPRANT
It’s only fair to share… ATICAPRANT JNJ-67953964, WHO 10582 1174130-61-0 BENZAMIDE, 4-(4-(((2S)-2-(3,5-DIMETHYLPHENYL)-1-PYRROLIDINYL)METHYL)PHENOXY)-3-FLUORO- C26H27FN2O2, 418.512 Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder.[2][3][4] A regulatory application for approval of the medication is expected to be submitted by 2025.[2] Aticaprant is taken by mouth.[1] Side effects of aticaprant include itching, …
ZASTAPRAZAN
It’s only fair to share… ZASTAPRAZAN 2133852-18-1 362.5 g/mol, C22H26N4O JAQBO; JP-1366; OCN-101; Zastaprazan citrate – Onconic Therapeutics, UNII-W9S9KZX5MD Highest Development Phases Zastaprazan (JP-1366) is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases. SCHEME Patent WO2018008929 PATENT KR1777971 //////////ZASTAPRAZAN, JAQBO, JP-1366, OCN-101, Zastaprazan citrate, Onconic Therapeutics, …
Evobrutinib
It’s only fair to share… Evobrutinib 429.5 g/mol,C25H27N5O2 Evobrutinib 1415823-73-2 Evobrutinib [INN] 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one MSC2364447C MSC2364447C M-2951 MSC-2364447C ZA45457L1K 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one M2951 Evobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability). Evobrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, evobrutinib inhibits the activity of …